# The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

> **NCT06117644** · — · NOT_YET_RECRUITING · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Gene Mutation
- Non Small Cell Lung Cancer Stage IIIA
- Non-small Cell Lung Cancer Stage IV

## Interventions

- **DRUG:** Furmonertinib

## Key facts

- **NCT ID:** NCT06117644
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-11-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06117644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06117644, "The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06117644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*